NSCLC metastatic/no molecular target

 
Ongoing protocols: click on the protocol for the inclusion and exclusion criteria (update 03/02/2020)

1st line
LUNG037 (Merck)
A Phase II, Multicenter, Randomized, Open-Label, Controlled Study of M7824 versus Pembrolizumab as a First-line Treatment in Patients with PD-L1 Expressing Advanced Non-small Cell Lung Cancer.


2th line 
Currently no trials

3th line 
Currently no trials